- Home
- APVO vs ONFO Comparison
APVO vs ONFO Comparison
Compare APVO & ONFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- ONFO
- Stock Information
- Founded
- APVO 2016
- ONFO 2018
- Country
- APVO United States
- ONFO United States
- Employees
- APVO N/A
- ONFO N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- ONFO Computer Software: Programming Data Processing
- Sector
- APVO Health Care
- ONFO Technology
- Exchange
- APVO Nasdaq
- ONFO Nasdaq
- Market Cap
- APVO 4.9M
- ONFO 5.0M
- IPO Year
- APVO N/A
- ONFO 2022
- Fundamental
- Price
- APVO $1.57
- ONFO $1.23
- Analyst Decision
- APVO Strong Buy
- ONFO
- Analyst Count
- APVO 1
- ONFO 0
- Target Price
- APVO $5,920.00
- ONFO N/A
- AVG Volume (30 Days)
- APVO 176.9K
- ONFO 1.6M
- Earning Date
- APVO 11-06-2025
- ONFO 11-14-2025
- Dividend Yield
- APVO N/A
- ONFO N/A
- EPS Growth
- APVO N/A
- ONFO N/A
- EPS
- APVO N/A
- ONFO N/A
- Revenue
- APVO N/A
- ONFO $10,508,728.00
- Revenue This Year
- APVO N/A
- ONFO N/A
- Revenue Next Year
- APVO N/A
- ONFO N/A
- P/E Ratio
- APVO N/A
- ONFO N/A
- Revenue Growth
- APVO N/A
- ONFO 78.36
- 52 Week Low
- APVO $1.41
- ONFO $0.61
- 52 Week High
- APVO $381.10
- ONFO $1.95
- Technical
- Relative Strength Index (RSI)
- APVO 47.04
- ONFO 54.42
- Support Level
- APVO N/A
- ONFO N/A
- Resistance Level
- APVO $1.54
- ONFO $1.20
- Average True Range (ATR)
- APVO 0.18
- ONFO 0.07
- MACD
- APVO -0.02
- ONFO -0.02
- Stochastic Oscillator
- APVO 57.55
- ONFO 93.40
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Onfolio LLC.